Redler Adriano, Di Rocco Giorgio, Giannotti Domenico, Frezzotti Francesca, Bernieri Maria Giulia, Ceccarelli Simona, D'Amici Sirio, Vescarelli Enrica, Mitterhofer Anna Paola, Angeloni Antonio, Marchese Cinzia
Department of Surgical Sciences, Sapienza University of Rome, Rome, Italy.
PLoS One. 2013 Aug 19;8(8):e72224. doi: 10.1371/journal.pone.0072224. eCollection 2013.
Fibroblast growth factor receptor-2 (FGFR-2) plays an important role in tumorigenesis. In thyroid cancer it has been observed a FGFR-2 down-modulation, but the role of this receptor has not been yet clarified. Therefore, we decided to examine the expression of both FGFR-2 isoform, FGFR-2-IIIb and FGFR-2-IIIc, in different histological thyroid variants such as hyperplasia, follicular adenoma and papillary carcinoma. Immunohistochemistry and quantitative Real-Time PCR analyses were performed on samples of hyperplasia, follicular adenoma and papillary carcinoma, compared with normal thyroid tissue. Thyroid hyperplasia did not show statistically significant reduction in FGFR-2 protein and mRNA levels. Interestingly, in both follicular adenoma and papillary carcinoma samples we observed a strongly reduced expression of both FGFR-2 isoforms. We speculate that FGFR-2 down-modulation might be an early event in thyroid carcinogenesis. Furthermore, we suggest the potential use of FGFR-2 as an early marker for thyroid cancer diagnosis.
成纤维细胞生长因子受体-2(FGFR-2)在肿瘤发生过程中发挥着重要作用。在甲状腺癌中,已观察到FGFR-2下调,但该受体的作用尚未阐明。因此,我们决定检测FGFR-2的两种异构体,即FGFR-2-IIIb和FGFR-2-IIIc,在不同组织学类型的甲状腺病变中的表达,如甲状腺增生、滤泡性腺瘤和乳头状癌。对甲状腺增生、滤泡性腺瘤和乳头状癌的样本进行免疫组织化学和定量实时PCR分析,并与正常甲状腺组织进行比较。甲状腺增生在FGFR-2蛋白和mRNA水平上未显示出统计学上的显著降低。有趣的是,在滤泡性腺瘤和乳头状癌样本中,我们均观察到两种FGFR-2异构体的表达均显著降低。我们推测FGFR-2下调可能是甲状腺癌发生的早期事件。此外,我们建议将FGFR-2作为甲状腺癌诊断的早期标志物。